Effectiveness of cognitive behavioral therapy on social anxiety disorder: A comparative study.
CBT
cognitive behavioral therapy
fear
negative evaluation
nonrandomized
paroxetine
social anxiety disorder
Journal
Industrial psychiatry journal
ISSN: 0972-6748
Titre abrégé: Ind Psychiatry J
Pays: India
ID NLM: 101547239
Informations de publication
Date de publication:
Historique:
received:
22
01
2020
revised:
07
05
2020
accepted:
27
05
2020
entrez:
29
3
2021
pubmed:
1
1
2020
medline:
1
1
2020
Statut:
ppublish
Résumé
Both cognitive behavior therapy (CBT) and paroxetine (PX) are the preferred treatments for social anxiety disorder (SAD). However, in literature, there have been divided opinions for the efficacy of the combination of these treatments. This study intended to evaluate whether the combination of CBT and PX would be superior to monotherapy of PX in the treatment of SAD. This was a single centre, rater-blind, non randomised study which included 40 consenting adult participants who received CBT+PX or PX only. The Liebowitz Social Anxiety Scale, Social Interaction Anxiety Scale, and Brief Fear of Negative Evaluation scale (BFNE) were assessed at baseline (0 weeks), immediate posttreatment (16-18 weeks for CBT + PX and 16-20 weeks for PX only), and at follow-ups 2 months after posttreatment. Both the treatment groups have a statistically significant difference in mean scores in all outcome measures in posttreatment and follow-up stages compared with pretreatment scores. However, CBT + PX has a better treatment and maintenance gain as compared to PX alone in the posttreatment and follow-up stages. In SAD management, combinations of CBT + PX are superior to PX alone, and the treatment gains are also better maintained in former than latter.
Sections du résumé
BACKGROUND
BACKGROUND
Both cognitive behavior therapy (CBT) and paroxetine (PX) are the preferred treatments for social anxiety disorder (SAD). However, in literature, there have been divided opinions for the efficacy of the combination of these treatments. This study intended to evaluate whether the combination of CBT and PX would be superior to monotherapy of PX in the treatment of SAD.
METHODS
METHODS
This was a single centre, rater-blind, non randomised study which included 40 consenting adult participants who received CBT+PX or PX only. The Liebowitz Social Anxiety Scale, Social Interaction Anxiety Scale, and Brief Fear of Negative Evaluation scale (BFNE) were assessed at baseline (0 weeks), immediate posttreatment (16-18 weeks for CBT + PX and 16-20 weeks for PX only), and at follow-ups 2 months after posttreatment.
RESULTS
RESULTS
Both the treatment groups have a statistically significant difference in mean scores in all outcome measures in posttreatment and follow-up stages compared with pretreatment scores. However, CBT + PX has a better treatment and maintenance gain as compared to PX alone in the posttreatment and follow-up stages.
CONCLUSIONS
CONCLUSIONS
In SAD management, combinations of CBT + PX are superior to PX alone, and the treatment gains are also better maintained in former than latter.
Identifiants
pubmed: 33776279
doi: 10.4103/ipj.ipj_2_20
pii: IPJ-29-76
pmc: PMC7989459
doi:
Types de publication
Journal Article
Langues
eng
Pagination
76-81Informations de copyright
Copyright: © 2020 Industrial Psychiatry Journal.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Arch Gen Psychiatry. 2010 Mar;67(3):286-95
pubmed: 20194829
Br J Psychiatry. 2001 Jul;179:23-30
pubmed: 11435264
Lancet Psychiatry. 2014 Oct;1(5):368-76
pubmed: 26361000
Indian J Psychiatry. 2019;61(4):424-426
pubmed: 31391653
Neuro Endocrinol Lett. 2006 Aug;27(4):473-81
pubmed: 16891998
Indian J Med Res. 2016 Apr;143(4):507-13
pubmed: 27377509
BMC Psychiatry. 2014;14 Suppl 1:S1
pubmed: 25081580
Dialogues Clin Neurosci. 2015 Sep;17(3):327-35
pubmed: 26487813
Int J Neuropsychopharmacol. 2013 Feb;16(1):235-49
pubmed: 22436306
J Anxiety Disord. 2012 Apr;26(3):393-400
pubmed: 22306132
Arch Gen Psychiatry. 2004 Oct;61(10):1005-13
pubmed: 15466674
Behav Res Ther. 1997 Aug;35(8):741-56
pubmed: 9256517
Eur J Med Chem. 2018 Feb 10;145:445-497
pubmed: 29335210
World Psychiatry. 2014 Feb;13(1):56-67
pubmed: 24497254
Clin Psychol (New York). 2010 Jun 1;17(2):91-103
pubmed: 26855480
Behav Res Ther. 1998 Apr;36(4):455-70
pubmed: 9670605
J Anxiety Disord. 2005;19(3):345-59
pubmed: 15686861
J Anxiety Disord. 2006;20(6):807-17
pubmed: 16368221
Psychol Med. 2001 Aug;31(6):1025-35
pubmed: 11513370
Ind Psychiatry J. 2018 Jan-Jun;27(1):53-60
pubmed: 30416292